BR112018017307A2 - molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus - Google Patents
molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírusInfo
- Publication number
- BR112018017307A2 BR112018017307A2 BR112018017307A BR112018017307A BR112018017307A2 BR 112018017307 A2 BR112018017307 A2 BR 112018017307A2 BR 112018017307 A BR112018017307 A BR 112018017307A BR 112018017307 A BR112018017307 A BR 112018017307A BR 112018017307 A2 BR112018017307 A2 BR 112018017307A2
- Authority
- BR
- Brazil
- Prior art keywords
- zika virus
- immune response
- methods
- nucleic acid
- zika
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662300030P | 2016-02-25 | 2016-02-25 | |
| US201662305183P | 2016-03-08 | 2016-03-08 | |
| US201662396742P | 2016-09-19 | 2016-09-19 | |
| US201662417100P | 2016-11-03 | 2016-11-03 | |
| US201762462249P | 2017-02-22 | 2017-02-22 | |
| PCT/US2017/019407 WO2017147458A1 (en) | 2016-02-25 | 2017-02-24 | Novel vaccines against zika virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018017307A2 true BR112018017307A2 (pt) | 2019-01-08 |
Family
ID=59685658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018017307A BR112018017307A2 (pt) | 2016-02-25 | 2017-02-24 | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11648303B2 (enExample) |
| EP (1) | EP3419660A4 (enExample) |
| JP (3) | JP7012365B2 (enExample) |
| KR (1) | KR20190003471A (enExample) |
| CN (2) | CN109152826B (enExample) |
| AU (3) | AU2017222644B2 (enExample) |
| BR (1) | BR112018017307A2 (enExample) |
| CA (1) | CA3015792A1 (enExample) |
| MX (2) | MX2018010291A (enExample) |
| WO (1) | WO2017147458A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| US11648303B2 (en) | 2016-02-25 | 2023-05-16 | The Trustees Of The University Of Pennsylvania | Vaccines against zika virus |
| CA3040123A1 (en) * | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
| US11806393B2 (en) * | 2017-02-10 | 2023-11-07 | La Jolla Institute For Allergy And Immunology | Flavivirus peptide sequences, epitopes, and methods and uses thereof |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| CA3081586A1 (en) | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| KR20200090893A (ko) | 2017-11-30 | 2020-07-29 | 다케다 백신즈 인코포레이티드 | 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들 |
| WO2019113285A2 (en) * | 2017-12-06 | 2019-06-13 | Emory University | Zika vaccines and methods of use |
| WO2020019024A1 (en) * | 2018-07-23 | 2020-01-30 | The University Of Adelaide | Zika virus vaccine |
| BR112021008217A2 (pt) * | 2018-10-31 | 2021-08-17 | Icahn School Of Medicine At Mount Sinai | anticorpos humanos que têm como alvo vírus zika ns1, polipeptídeos ns1 e seus usos |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| CN117120617A (zh) * | 2021-02-05 | 2023-11-24 | St制药株式会社 | 新型核酸分子 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000014245A1 (en) * | 1998-09-02 | 2000-03-16 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Dengue viruses that are replication defective in mosquitos for use as vaccines |
| US7767210B2 (en) * | 2005-12-14 | 2010-08-03 | The Board Of Regents Of The University Of Oklahoma | RNA virus vaccines and methods |
| ES2685435T3 (es) * | 2008-01-11 | 2018-10-09 | Inovio Pharmaceuticals, Inc. | Nuevas vacunas frente a múltiples subtipos del virus del dengue |
| CN105400798A (zh) | 2008-11-17 | 2016-03-16 | Vgx药品有限责任公司 | 引起对抗黄病毒的免疫应答的抗原及其应用方法 |
| US8624011B2 (en) * | 2009-09-14 | 2014-01-07 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
| JP2013509203A (ja) | 2009-11-02 | 2013-03-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 口蹄疫ウイルス（ｆｍｄｖ）コンセンサスタンパク質、そのコード配列およびそれから生成されるワクチン |
| US8691961B1 (en) | 2009-11-09 | 2014-04-08 | Integral Molecular, Inc. | Flavivirus reporter virus and methods of making and using the same |
| WO2011115583A1 (en) * | 2010-03-19 | 2011-09-22 | National University Of Singapore | A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens |
| EP2550292B1 (en) * | 2010-03-24 | 2017-11-22 | Research Development Foundation | Flavivirus host range mutations and uses thereof |
| CN103476928B (zh) * | 2010-12-09 | 2017-03-29 | 巴斯德研究所 | 用于获得高产量重组蛋白表达的基于mgmt的方法 |
| AU2012212264B2 (en) | 2011-01-31 | 2016-01-28 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| EP2788478B1 (en) * | 2011-12-09 | 2017-08-23 | Institut Pasteur | Multiplex immuno screening assay |
| CA2906082A1 (en) | 2013-03-15 | 2014-09-18 | Inovio Pharmaceuticals, Inc. | Novel vaccines against multiple subtypes of dengue virus |
| KR20180036987A (ko) * | 2015-07-16 | 2018-04-10 | 브하라트 바이오테크 인터내셔날 리미티드 | 백신 조성물 |
| TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
| WO2017070624A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| MX2018009917A (es) * | 2016-02-17 | 2019-08-14 | Curevac Ag | Vacuna contra el virus del zika. |
| US11648303B2 (en) * | 2016-02-25 | 2023-05-16 | The Trustees Of The University Of Pennsylvania | Vaccines against zika virus |
| EP3484511A4 (en) * | 2016-07-18 | 2020-04-29 | Variation Biotechnologies Inc. | Vaccine compositions for treatment of zika virus |
| CA3037486A1 (en) * | 2016-09-19 | 2018-03-22 | The Trustees Of The University Of Pennsylvania | Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus |
| JP7317715B2 (ja) * | 2017-01-11 | 2023-07-31 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ジカウイルスに対する免疫応答を誘導するためのヌクレオシド改変ｒｎａ |
| EP3412307A1 (en) * | 2017-06-07 | 2018-12-12 | Institut Pasteur | Recombinant measles virus expressing zika virus proteins and their applications |
-
2017
- 2017-02-24 US US16/078,270 patent/US11648303B2/en active Active
- 2017-02-24 EP EP17757325.0A patent/EP3419660A4/en active Pending
- 2017-02-24 BR BR112018017307A patent/BR112018017307A2/pt unknown
- 2017-02-24 KR KR1020187027172A patent/KR20190003471A/ko active Pending
- 2017-02-24 AU AU2017222644A patent/AU2017222644B2/en active Active
- 2017-02-24 CA CA3015792A patent/CA3015792A1/en active Pending
- 2017-02-24 MX MX2018010291A patent/MX2018010291A/es unknown
- 2017-02-24 WO PCT/US2017/019407 patent/WO2017147458A1/en not_active Ceased
- 2017-02-24 CN CN201780017976.1A patent/CN109152826B/zh active Active
- 2017-02-24 CN CN202211273088.5A patent/CN115927399A/zh active Pending
- 2017-02-24 JP JP2018544819A patent/JP7012365B2/ja active Active
-
2018
- 2018-08-24 MX MX2023006203A patent/MX2023006203A/es unknown
-
2021
- 2021-10-29 AU AU2021258056A patent/AU2021258056B2/en active Active
- 2021-11-22 JP JP2021189383A patent/JP7555325B2/ja active Active
-
2023
- 2023-05-16 US US18/318,061 patent/US12419945B2/en active Active
-
2024
- 2024-04-30 JP JP2024073806A patent/JP2024096281A/ja active Pending
- 2024-07-04 AU AU2024204641A patent/AU2024204641A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021258056B2 (en) | 2024-04-04 |
| AU2017222644B2 (en) | 2021-07-29 |
| CN109152826B (zh) | 2022-11-04 |
| EP3419660A4 (en) | 2019-11-06 |
| WO2017147458A1 (en) | 2017-08-31 |
| US11648303B2 (en) | 2023-05-16 |
| US20240115689A1 (en) | 2024-04-11 |
| KR20190003471A (ko) | 2019-01-09 |
| JP2024096281A (ja) | 2024-07-12 |
| AU2021258056A1 (en) | 2021-11-25 |
| US12419945B2 (en) | 2025-09-23 |
| US20210315987A1 (en) | 2021-10-14 |
| MX2023006203A (es) | 2023-06-12 |
| EP3419660A1 (en) | 2019-01-02 |
| JP7012365B2 (ja) | 2022-03-04 |
| JP2022023241A (ja) | 2022-02-07 |
| AU2017222644A1 (en) | 2018-09-13 |
| MX2018010291A (es) | 2019-06-06 |
| JP7555325B2 (ja) | 2024-09-24 |
| AU2024204641A1 (en) | 2024-07-25 |
| CN109152826A (zh) | 2019-01-04 |
| CN115927399A (zh) | 2023-04-07 |
| CA3015792A1 (en) | 2017-08-31 |
| JP2019506175A (ja) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| CL2021000636A1 (es) | Vacuna contra el virus de la peste porcina africana | |
| BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
| CL2019000704A1 (es) | Vectores de adenovirus canino. | |
| BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| BR112018012873A2 (pt) | vacina de vírus zika | |
| BR112013032251A2 (pt) | composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina | |
| MX392857B (es) | Nuevos virus de tilapia y sus usos. | |
| BR112013020070A8 (pt) | moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas | |
| BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
| BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica | |
| BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
| BR112018016912A2 (pt) | novo antígeno para uso na vacina contra malária | |
| BR112016026651A2 (pt) | evolução de vesículas semelhantes a vírus de alta titulação para aplicações de vacina | |
| BR112014023414A2 (pt) | vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos | |
| BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
| CL2012000783A1 (es) | Proceso para mejorar la eficacia de proteccion metodo para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de dna y virus quimericos 17d; composicion vacunal que comprende vacunas de dna contra los cuatro serotipos del virus dengue y virus quimericos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína e. | |
| EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением | |
| BR112013013016A2 (pt) | modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14 | |
| BR112014023283A8 (pt) | Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza | |
| BR112017004356A2 (pt) | antígenos de streptococcus agalactiae associados a cepas virulentais em peixes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |